

Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019

<https://marketpublishers.com/r/T6203228B066EN.html>

Date: December 2019

Pages: 81

Price: US\$ 3,500.00 (Single User License)

ID: T6203228B066EN

Abstracts

Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019

SUMMARY

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) pipeline Target constitutes close to 25 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) or Death receptor 5 (DR5) is a protein encoded by TNFRSF10B. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL) and thus transduces cell death signal and induces cell apoptosis. It promotes the activation of NF-kappa-B. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 5, 11, 4 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology,

Gastrointestinal, Hematological Disorders, Immunology and Respiratory which include indications Colorectal Cancer, Solid Tumor, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Colon Carcinoma, Diffuse Large B-Cell Lymphoma, Esophageal Cancer, Gastrointestinal Tract Cancer, Glioma, Hematological Tumor, Liver Cancer, Liver Cirrhosis, Liver Fibrosis, Lung Cancer, Malignant Ascites, Malignant Glioma, Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Pancreatitis, Peritoneal Cancer, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Sarcomas, Systemic Sclerosis (Scleroderma), T-Cell Leukemia and Transitional Cell Cancer (Urothelial Cell Cancer).

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B)

The report reviews Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics and enlists all their major and minor projects

The report assesses Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Overview

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Companies Involved in Therapeutics Development

AbbVie Inc

Apollo Therapeutics LLC

AstraZeneca Plc

Beijing Sinotau Pharmaceutical Technology Co Ltd

Beijing Sunbio Biotech Co Ltd

Biomirex Inc

Boehringer Ingelheim International GmbH

Chengdu Huachuang Biotechnology Co Ltd

Clover Biopharmaceuticals

D&D Pharmatech Co Ltd

Daiichi Sankyo Co Ltd

Galaxy Biotech LLC

Genmab A/S

i2 Pharmaceuticals Inc

IGM Biosciences Inc

Inhibrx Inc

JN Biosciences LLC

MacroGenics Inc

Neonc Technologies Inc

Obio Technology (Shanghai) Corp Ltd

Polaris Pharmaceuticals Inc

Shanghai Gebaide Biotechnology Co Ltd

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Drug Profiles

ABBV-621 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AD-510 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-905711 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Antibody to Agonize EPHB6 and DR5 for Triple-Negative Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CD19L-sTRAIL - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTB-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-8273 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dulanermin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Agonize TRAIL Receptor-2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GEN-1029 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HuG-4.2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HuGOH-729S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INBRX-109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-3039 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize DR5 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Agonize DR5 for Hematological Tumor and Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Agonize TRAILR2 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-214 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

POL-30000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize TNFRSF10A, TNFRSF10B, TNFRSF10C and TNFRSF10D for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCB-313 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-231 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize DR4 and DR5 for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TLY-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Dormant Products

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF

Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Discontinued Products

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Product Development Milestones

Featured News & Press Releases

Nov 21, 2019: Clover Biopharmaceuticals doses first patient in Phase I study of SCB-313 in Australia for Malignant Pleural Effusions (MPE)

Sep 29, 2019: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Malignant Ascites

Sep 24, 2019: Theraly Fibrosis granted US Orphan Drug Designation for TLY012 for chronic pancreatitis

Sep 10, 2019: Clover Biopharmaceuticals doses first patient in phase I study of SCB-313 in China for Peritoneal Carcinomatosis

Sep 03, 2019: Inhibrx reports phase 1 dose escalation results of INBRX-109, a multivalent agonist of death receptor 5

May 30, 2019: AbbVie presents update on ABBV-621 at the 2019 ASCO

May 07, 2019: Clover Biopharmaceuticals receives NMPA approval for SCB-313 (TRAIL-Trimer) to initiate clinical trials in China

Dec 06, 2018: Inhibrx Announces Dosing of First Patients in Phase 1 Dose-Escalation Study of INBRX-109, a Novel Multivalent Agonist of Death Receptor 5 (DR5)

Dec 04, 2018: iDD biotech receives second milestone payment from Genmab with enrolment of fifth patient in Gen1029 safety trial

Jun 18, 2018: Clover Biopharmaceuticals Doses First Patient in Australia in Phase I Study of SCB-313 for Malignant Ascites

Nov 21, 2017: AbbVie to Present Data on Cancer Drug Candidate ABBV-621 at the 2017 American Society of Hematology Annual Meeting & Exposition

Apr 11, 2017: Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Apollo Therapeutics LLC, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Beijing Sinotau Pharmaceutical Technology Co Ltd, H2 2019
Pipeline by Beijing Sunbio Biotech Co Ltd, H2 2019
Pipeline by Biomirex Inc, H2 2019
Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Pipeline by Chengdu Huachuang Biotechnology Co Ltd, H2 2019
Pipeline by Clover Biopharmaceuticals, H2 2019
Pipeline by D&D Pharmatech Co Ltd, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Galaxy Biotech LLC, H2 2019
Pipeline by Genmab A/S, H2 2019
Pipeline by i2 Pharmaceuticals Inc, H2 2019
Pipeline by IGM Biosciences Inc, H2 2019
Pipeline by Inhibrx Inc, H2 2019
Pipeline by JN Biosciences LLC, H2 2019
Pipeline by MacroGenics Inc, H2 2019
Pipeline by Neonc Technologies Inc, H2 2019

Pipeline by Obio Technology (Shanghai) Corp Ltd, H2 2019

Pipeline by Polaris Pharmaceuticals Inc, H2 2019

Pipeline by Shanghai Gebaide Biotechnology Co Ltd, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

AbbVie Inc

Apollo Therapeutics LLC

AstraZeneca Plc

Beijing Sinotau Pharmaceutical Technology Co Ltd

Beijing Sunbio Biotech Co Ltd

Biomirex Inc

Boehringer Ingelheim International GmbH

Chengdu Huachuang Biotechnology Co Ltd

Clover Biopharmaceuticals

D&D Pharmatech Co Ltd

Daiichi Sankyo Co Ltd

Galaxy Biotech LLC

Genmab A/S

i2 Pharmaceuticals Inc

IGM Biosciences Inc

Inhibrx Inc

JN Biosciences LLC

MacroGenics Inc

Neonc Technologies Inc

Obio Technology (Shanghai) Corp Ltd

Polaris Pharmaceuticals Inc

Shanghai Gebaide Biotechnology Co Ltd

I would like to order

Product name: Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/T6203228B066EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T6203228B066EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970